SLA2 (Src like adaptor 2) functions as a negative regulator of T-cell receptor (TCR) signaling in hematopoietic cells 1. The protein inhibits T-cell antigen-receptor induced activation by linking signaling proteins such as ZAP70 with CBL, leading to CBL-dependent degradation of signaling proteins 1. SLA2 is expressed specifically in hematopoietic cell lines of both lymphoid and myeloid lineages, with the human gene located on chromosome 20 consisting of seven exons 1. Multiple protein isoforms exist due to alternative translation initiation and splicing, including a variant (SLAP-2-v) that lacks the c-Cbl interaction region and shows impaired ability to inhibit TCR signaling 1. In cancer contexts, particularly head and neck squamous cell carcinoma (HNSCC), elevated SLA2 expression correlates with favorable prognosis and increased immune cell infiltration including B cells, CD8+ T cells, CD4+ T cells, macrophages, neutrophils, and dendritic cells 2. The protein is involved in membrane-associated processes including endocytosis, with its ANTH domain forming complexes through phosphatidylinositol 4,5-bisphosphate (PIP2) lipid interfaces 3. SLA2 appears to regulate tumor development through modulation of tumor-infiltrating cells in the tumor microenvironment 2.